Osiris Therapeutics, Inc. has entered into an agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, Osiris will commercialize Prochymal in the United States and Canada, and Genzyme will commercialize the therapies in all other countries.

Osiris joined JCR Pharmaceutical Corporation to produce and market Prochymal in Japan, if and when it becomes commercially available.

Osiris partnered with the Juvenile Diabetes Research Foundation (JDRF) for the development of Prochymal as a treatment for patients with newly diagnosed type 1 diabetes mellitus.  Under the terms of the agreement, the JDRF has provided $4 million in funding to support the Phase II clinical trial activities.

In July 2008, Osiris sold the Osteocel business to NuVasive for $85 million.